semaglutide and tylenol The letter cited three deaths among patients using semaglutide, the active ingredient in several of its weight-loss medications, which it said were not properly investigated or reported. Read more at the link Do the New Obesity Drugs

Tirzepatide (Dual Receptor) Mounjaro FDA-approved for type 2 diabetes Zepbound FDA-approved for obesity Tirzepatide activates two receptors: GLP-1 and GIP

Despite a small detectable increase in birth weight of newborns from GLP-1-exposed pregnancies, there was no increased risk of large or small for gestational age birth weight or cesarean delivery associated with pre-pregnancy or early pregnancy GLP-1 use, Maya and colleagues wrote

Bookmark this page for regular reference because dosing guidelines are updated as new clinical data becomes available

FDA Disclaimer: This product is not intended to diagnose, treat, cure, or prevent any disease